ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1205

Soluble Vascular Biomarkers in Rheumatoid Arthritis and Ankylosing Spondylitis: Effects of One-year Anti-TNF-α Therapy

Anita Pusztai1, Attila Hamar2, Ágnes Horváth2, Katalin Gulyás2, Edit Végh2, Nóra Bodnár2, György Kerekes2, Monika Czókolyová2, Szilvia Szamosi2, Levente Bodoki2, Katalin Hodosi2, Andrea Domján2, Gábor Nagy2, Luis Lopez3, Ejii Matsuura4, Zoltán Prohászka5, Sándor Szántó2, Zoltán Nagy2, Yehuda Shoenfeld6, Zoltán Szekanecz2 and Gabriella Szűcs2, 1University of Debrecen Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary, 2University of Debrecen, Debrecen, Hungary, 3Corgenix Inc., Broomfield, CO, 4Okayama University, Okayama, Japan, 5Semmelweis University, Budapest, Hungary, 6Zabludowicz Center, Tel-Hashomer, Israel

Meeting: ACR Convergence 2020

Keywords: , ,

Session Information

Date: Sunday, November 8, 2020

Title: RA – Treatments Poster III: PROs, Biomarkers, Systemic Inflammation & Radiographs

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have been associated with cardiovascular (CV) disease. The treatment of arthritis by tumour necrosis factor α (TNF-α) inhibitors may decrease the serum concentrations of vascular biomarkers. We determined circulating levels of oxidized LDL (oxLDL)/β2 glycoprotein I (β2GPI) complexes, antibodies to 60 kDa heat shock protein (anti-Hsp60), soluble urokinase plasminogen activator receptor (suPAR) and  Brain type natriuretic peptide (BNP) fragment in sera of RA and AS patients undergoing anti-TNF treatment. 

Methods: Fifty-three RA/AS patients were treated with etanercept (ETN) or certolizumab pegol (CZP) for one year. Circulating oxLDL/β2GPI complex (AtherOx®), anti-Hsp60 IgG and BNP8-29 fragment levels were assessed by ELISA. suPAR levels were determined by suPARnostic® Quick Triage test. Flow-mediated vasodilation (FMD), carotid intima-media thickness (IMT) and arterial pulse-wave velocity (PWV) were determined by ultrasound.

Results: One-year anti-TNF treatment significantly decreased oxLDL/β2GPI levels, as well as suPAR levels in patients with “critically” high suPAR levels at baseline. In RA, BNP levels were higher in seropositive vs seronegative patients. Serum levels of these vascular biomarkers variably correlated with lipids, ACPA, RF and CRP. IMT positively correlated with BNP, PWV with suPAR and anti-Hsp60, while FMD inversely associated with anti-Hsp60. In RM-ANOVA analysis, disease activity supported the effects of anti-TNF treatment on 12-month changes in oxLDL/β2GPI. IMT supported the effects of therapy on changes of anti-Hsp60 and suPAR.

Conclusion: These biomarkers may be involved in the pathogenesis of atherosclerosis underlying RA/AS. TNF inhibition variably affect the serum levels of oxLDL/β2GPI, suPAR and BNP.

Disclosure: A. Pusztai, None; A. Hamar, None; �. Horváth, None; K. Gulyás, None; E. Végh, None; N. Bodnár, None; G. Kerekes, None; M. Czókolyová, None; S. Szamosi, None; L. Bodoki, None; K. Hodosi, None; A. Domján, None; G. Nagy, None; L. Lopez, Corgenix Inc, 1; E. Matsuura, None; Z. Prohászka, None; S. Szántó, None; Z. Nagy, None; Y. Shoenfeld, None; Z. Szekanecz, Pfizer, 1; G. Szűcs, None.

To cite this abstract in AMA style:

Pusztai A, Hamar A, Horváth �, Gulyás K, Végh E, Bodnár N, Kerekes G, Czókolyová M, Szamosi S, Bodoki L, Hodosi K, Domján A, Nagy G, Lopez L, Matsuura E, Prohászka Z, Szántó S, Nagy Z, Shoenfeld Y, Szekanecz Z, Szűcs G. Soluble Vascular Biomarkers in Rheumatoid Arthritis and Ankylosing Spondylitis: Effects of One-year Anti-TNF-α Therapy [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/soluble-vascular-biomarkers-in-rheumatoid-arthritis-and-ankylosing-spondylitis-effects-of-one-year-anti-tnf-%ce%b1-therapy/. Accessed .

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/soluble-vascular-biomarkers-in-rheumatoid-arthritis-and-ankylosing-spondylitis-effects-of-one-year-anti-tnf-%ce%b1-therapy/